Literature DB >> 31025312

Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.

Margherita Fabbri1,2, Chatkaew Pongmala1, Carlo Alberto Artusi1, Alberto Romagnolo1, Mario Giorgio Rizzone1, Maurizio Zibetti1, Leonardo Lopiano1.   

Abstract

BACKGROUND: Few studies have suggested that levodopa-carbidopa intestinal gel (LCIG) may have a benefit on Parkinson's disease (PD) axial signs. AIMS OF THE STUDY: To investigate the long-term effect of LCIG on axial signs and the related prognostic factors.
METHODS: A retrospective study on 49 PD patients treated with LCIG. Axial signs as per the Unified Parkinson Disease Rating Scale axial score (AS), Hoehn and Yahr (H&Y) scale, and levodopa equivalent daily dose (LEDD) were assessed at baseline (before starting LCIG treatment) and at the last follow-up (FU).
RESULTS: After 47.6 ± 30 months of treatment, total AS deteriorated while motor complications still improved, in spite of a significant LEDD/Kg increment. When adjusted for LCIG treatment duration, a higher AS and freezing of gait severity at FU were predicted by a baseline lower response to l-dopa and higher H&amp;Y (P < 0.01) and they were related to a lower independency in activity of daily life at FU (P < 0.001). Single axial items remain stable up to one year and postural instability up to four years.
CONCLUSION: Baseline disease severity and the magnitude of l-dopa response predict axial signs' severity after around four years of LCIG treatment, with consequent implication on patients' functional independence.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Parkinson’s disease; axial signs; gait; levodopa-carbidopa intestinal gel

Mesh:

Substances:

Year:  2019        PMID: 31025312     DOI: 10.1111/ane.13110

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

Review 1.  Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.

Authors:  Taiji Tsunemi; Genko Oyama; Shinji Saiki; Taku Hatano; Jiro Fukae; Yasushi Shimo; Nobutaka Hattori
Journal:  Mov Disord       Date:  2021-04-25       Impact factor: 9.698

2.  Outcome Measures for Evaluating the Effect of a Multidisciplinary Intervention on Axial Symptoms of Parkinson's Disease.

Authors:  Raquel Bouça-Machado; Filipa Pona-Ferreira; Nilza Gonçalves; Mariana Leitão; Ricardo Cacho; Ana Castro-Caldas; Joaquim J Ferreira
Journal:  Front Neurol       Date:  2020-05-12       Impact factor: 4.003

3.  Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Unresponsive Freezing of Gait after Deep Brain Stimulation in Parkinson's Disease.

Authors:  Belén González-Herrero; Serge Jauma-Classen; Roser Gómez-Llopico; Gerard Plans; Matilde Calopa
Journal:  Parkinsons Dis       Date:  2020-05-14

4.  DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.

Authors:  David G Standaert; Jason Aldred; Marieta Anca-Herschkovitsch; Paul Bourgeois; Esther Cubo; Thomas L Davis; Robert Iansek; Norbert Kovács; Francesco E Pontieri; Mustafa S Siddiqui; Mihaela Simu; Lars Bergmann; Pavnit Kukreja; Weining Z Robieson; K Ray Chaudhuri
Journal:  Mov Disord Clin Pract       Date:  2021-09-12

5.  Technology-based therapy-response evaluation of axial motor symptoms under daily drug regimen of patients with Parkinson's disease.

Authors:  Zhuang Wu; Ronghua Hong; Shuangfang Li; Kangwen Peng; Ao Lin; Yichen Gao; Yue Jin; Xiaoyun Su; Hongping Zhi; Qiang Guan; Lizhen Pan; Lingjing Jin
Journal:  Front Aging Neurosci       Date:  2022-08-05       Impact factor: 5.702

Review 6.  Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson's disease.

Authors:  Melanie R Shackleford; Virendra Mishra; Zoltan Mari
Journal:  Clin Park Relat Disord       Date:  2022-06-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.